Acquired angioedema: a new target for rituximab?
Ziakas
Panayiotis D
PD
Giannouli
Stavroula
S
Psimenou
Erasmia
E
Evangelia
Kompoti
K
Tzioufas
Athanasios G
AG
Voulgarelis
Michalis
M
D000799:Angioedema / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003167:Complement Activation; D003172:Complement C1 / Q000172:deficiency; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003172:Complement C1; D007155:Immunologic Factors; D000069283:Rituximab